This research investigates the safety of targeted synthetic DMARDs during pregnancy in people with autoimmune joint diseases. Using 20 years of population-level health data, it identifies increased risk of low birth weight associated with prenatal exposure. The findings aim to inform clinical guidance and empower patients to make safer, evidence-based decisions about pregnancy.

My research uses spatial RNA sequencing to map where genes are expressed within tissues affected by chronic inflammatory diseases. By capturing genetic information with precise spatial coordinates, it creates an atlas of disease-driving genes. This deeper understanding may reveal new biomarkers and therapeutic targets, enabling future treatments beyond symptom management.